TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05601180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respicure®
Description: Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: standard treatment is prescribed by the treating physician.
Study: NCT05023070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Epidiolex 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol 400 mg
Study: NCT06351085

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-Visit Planner
Description: The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-Visit Planner + MyChart
Description: The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process as well as testing if watching educational videos about the Lung Cancer Screening (LCS) process prior to talking to an LVN will help with LCS uptake.
Study: NCT05301582

Intervention type: DIAGNOSTIC_TEST
Intervention: Tidal volume challenge test
Description: The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
Study: NCT05937620

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTC nanocolloid albumin injection
Description: All patients will receive an injection of both tracers in order to detect the sentinel lymph node

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG injection
Description: All patients will receive an injection of both tracers in order to detect the sentinel lymph node
Study: NCT06349707

Intervention type: OTHER
Intervention: other: Observational
Description: For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)
Study: NCT05667506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously.~Lymphodepletion treatment:~Drugs:Fludarabine Drugs: Cyclophosphamide
Study: NCT05205200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: PD-L1 antibody

Intervention type: DRUG
Group type: OTHER
Intervention: SHR-1316
Description: PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR6390
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Albumin bound paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Albumin bound paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD
Description: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERD
Description: Fulvestrant

Intervention type: DRUG
Group type: OTHER
Intervention: SERD
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI
Description: aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI
Description: aromatase inhibitor
Study: NCT04653259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LYFE MD app
Description: LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives.
Study: NCT06195176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder exercises
Description: Operational Definition:~* Lift the shoulders as high as possible toward the ears.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hand exercises
Description: Operational Definition:~* Open and close the hands, making a fist and applying force.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night.
Study: NCT05064579

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
Study: NCT06052514

Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: Patients with moderate or severe OSA will be treated with CPAP
Study: NCT06215209

Intervention type: OTHER
Intervention: position
Description: patients will be in supine position and prone position
Study: NCT04797390

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Pneumatic Compression Device (APCD)
Description: Once daily treatment with Flexitouch Plus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of a two-phase CDT. Phase 1 includes consultation with a lymphedema therapist, patient education, MLD, compression garments or bandages, skin care techniques, and a program of exercises and postural recommendations. Phase 2 consists of ongoing self-care, where patients conduct a life-long program of disease management that mimics the program in phase 1.
Study: NCT06145113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP), ResMed AirMini
Description: Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP), ResMed AirMini
Description: Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP), ResMed AirMini
Description: Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
Study: NCT04551768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Study: NCT05028205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus
Description: Families will receive a behavioral intervention for childhood obesity provided by a BHC. This will consist of three, in-person meetings (months 1, 3, and 5), and three, 20-minute phone calls (months 2,4, and 6). During in-person visits, child height and weight will be taken, and BMI will be plotted on the BMI-for-age growth chart. During these sessions, families will receive feedback on child growth and weight status. Prevention Plus materials and child and caregiver energy balance behavior goals will be reviewed. The phone calls will be with the caregiver, where caregivers will be asked to measure the height and weight of their child, calculate BMI, and plot on the BMI-for-age growth chart. The BHC will discuss the family's progress on achieving child and caregiver goals and implementation of behavioral parenting strategies. Families will receive a fruit and vegetable prescription (FVx) in addition to the standard Prevention Plus family-based behavioral weight loss treatment.
Study: NCT05530356

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: DRUG
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: DRUG
Intervention: Dextran 40
Description: Diagnostic aid/agent used to measure glomerular size selectivity

Intervention type: DRUG
Intervention: Dextran 40
Description: Diagnostic aid/agent used to measure glomerular size selectivity

Intervention type: DRUG
Intervention: Dextran 40
Description: Diagnostic aid/agent used to measure glomerular size selectivity

Intervention type: PROCEDURE
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.

Intervention type: RADIATION
Intervention: Positron Emission Tomography
Description: Imaging study performed to study renal oxidative metabolism

Intervention type: RADIATION
Intervention: Positron Emission Tomography
Description: Imaging study performed to study renal oxidative metabolism
Study: NCT05306886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICB Medical Insoles
Description: After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICM Insoles
Description: As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
Study: NCT06160661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular saggital split osteotomy
Description: orthognathic surgery
Study: NCT04670445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video and QPL List
Description: The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video and QPL List
Description: The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Surveys
Study: NCT05926869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Dapsone gel for 03 months
Description: Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Dapsone gel for 03 months
Description: Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
Study: NCT05295199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
Study: NCT04617405

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT05206396

Intervention type: DIAGNOSTIC_TEST
Intervention: TIL assessment in pre-existing histopathological specimens
Description: TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
Study: NCT05658653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials for Chronic Disease Management Test (CDMT)
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study: NCT05337423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Group 1 will receive 630 nm LED and group 2 will receive sham treatment twice a week in the palmo-plantar areas of the hands and feet (4 J/cm2) for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: Both groups will receive moisturizer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Moisturizer
Description: Both groups will receive moisturizer.
Study: NCT04765878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAq Humidification
Description: Humidifier
Study: NCT05707897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Description: Single-dose of 10 mg of TS-142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142 10 mg
Description: Single-dose of 10 mg of TS-142
Study: NCT05317442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon Cream
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks
Study: NCT04953962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 (16)
Description: 16 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 (25)
Description: 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 (25)
Description: 25 mg/m2
Study: NCT05899790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: The first interview with the patients in the intervention group will be held in the afternoon, the day before the surgery. After completing the forms and scale the video containing information about the operating room environment will be applied to the patients through SG glasses and headphones.~Before the surgical intervention, patients admitted to the pre-operative waiting area from the clinic, the video containing information about the operating room environment will be watched by the patients through SG glasses and headphones.
Study: NCT05420051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: The 8-week PP-MI intervention focuses on enhancing well-being (through PP) and increasing physical activity (through MI). Each week, participants will complete a PP activity and work towards a physical activity goal, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to improve physical activity levels, resolve ambivalence to behavior change, set realistic physical activity goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage completion of PP activities and engagement in physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The 8-week MI-alone intervention focuses on providing education and enhancing motivation to engage in health behaviors (through MI). Each week, participants will complete an activity related to a health behavior (e.g., consider the pros and cons of behavior change, set a health behavior goal), then complete a phone session with a study trainer. This program will focus on assisting participants to improve health behavior adherence (including physical activity), resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Additional time in MI-alone phone sessions will be spent on review of core MI skills, problem-solving of barriers, and discussion of resources. Finally, participants will receive twice weekly text messages (for 16 weeks) to encourage engagement in health behaviors.
Study: NCT05764122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB131
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB131
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB131
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT06263322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actionable remotely generated health data
Description: Remotely captured, patient generated health data will be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Actionable remotely generated health data
Description: Remotely captured, patient generated health data is captured, but will not be used to inform provider care following re-vascular surgery in patients with chronic limb threatening ischemia
Study: NCT05115032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular retraining with dynamic posturography
Description: 12 sessions, twice per week, of rehabilitation exercises last about 20 minutes, using CDP and interactive visual feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At-home rehabilitation exercises
Description: 6 weeks of daily rehabilitation exercises involving nodding and shaking of the head
Study: NCT06455826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-001
Description: A Phase 1 Open-Label, Multiple Ascending Dose Study of VP-001 in Participants with Confirmed PRPF31 Mutation- Associated Retinal Dystrophy
Study: NCT04963426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral interventions targeting multiple risk behaviors as well as protective factors
Description: Depending on the baseline data and prioritization of actions, behavioral interventions related to the following topics will be implemented: alcohol use, dietary behaviors, drug use, hygiene, mental health, physical activity, protective factors, sexual behaviors, tobacco use, violence and unintentional injury.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-level interventions targeting the school environment and system
Description: Depending on the baseline data and prioritization of actions, and based on the Global Standards for Health Promoting Schools, school-level interventions related to the following will be implemented: school policies and resources, school governance and leadership, school and community partnerships, school curriculum, school social-emotional environment, school physical environment, school health services